Evercore ISI initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report released on Thursday morning. The firm issued an in-line rating and a $20.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC set a $25.00 target price on shares of Nektar Therapeutics and gave the company a buy rating in a research note on Saturday, April 22nd. BidaskClub raised shares of Nektar Therapeutics from a sell rating to a hold rating in a research note on Thursday. William Blair reissued an outperform rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research note on Monday, August 7th. They set a buy rating and a $31.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Nektar Therapeutics from a buy rating to a hold rating in a research note on Friday, August 11th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics has a consensus rating of Buy and a consensus target price of $26.10.

Shares of Nektar Therapeutics (NKTR) traded down 1.57% during trading on Thursday, hitting $18.13. 775,121 shares of the stock traded hands. The company has a 50 day moving average price of $20.53 and a 200 day moving average price of $18.52. The firm’s market cap is $2.83 billion. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. The company had revenue of $34.60 million for the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.36) EPS. Analysts anticipate that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nektar Therapeutics (NKTR) Now Covered by Analysts at Evercore ISI” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/18/nektar-therapeutics-nktr-now-covered-by-analysts-at-evercore-isi.html.

In other news, Director Roy A. Whitfield bought 35,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $17.95 per share, with a total value of $628,250.00. Following the completion of the acquisition, the director now owns 133,000 shares of the company’s stock, valued at $2,387,350. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Ivan P. Gergel sold 54,920 shares of Nektar Therapeutics stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total transaction of $1,158,812.00. Following the completion of the transaction, the senior vice president now directly owns 98,492 shares of the company’s stock, valued at $2,078,181.20. The disclosure for this sale can be found here. Insiders have sold 138,389 shares of company stock worth $2,908,403 in the last three months. 6.10% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. Flinton Capital Management LLC boosted its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares during the period. Meadow Creek Investment Management LLC boosted its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares during the period. LS Investment Advisors LLC boosted its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the period. Finally, Glen Harbor Capital Management LLC boosted its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares during the period. 93.02% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.